Peritumoral brain edema in angiomatous supratentorial meningiomas: An investigation of the vascular endothelial growth factor A pathway

APMIS

Volumn 121, Issue 11, 2013, Pages 1025-1036

  Nassehi, Damoun ^a,b   Sørensen, Lars P ^b   Dyrbye, Henrik ^b   Thomsen, Carsten ^c   Juhler, Marianne ^a   Laursen, Henning ^b   Broholm, Helle ^b  

^a Department of Neurosurgery ^*  (Denmark)

^b Neuropathology Laboratory   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

Brain edema; Meningioma; Neuropilin 1; Vascular endothelial growth factor A; Vascular endothelial growth factor 2

Indexed keywords

CD34 ANTIGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; NEUROPILIN 1; PROGESTERONE RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ANGIOMATOUS SUPRATENTORIAL MENINGIOMA; ARTICLE; BLOOD VESSEL PARAMETERS; BRAIN EDEMA; CAPILLARY LENGTH; CAPILLARY PROLIFERATION; CHEMOLUMINESCENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PERITUMORAL BRAIN EDEMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TISSUE SECTION;

BRAIN EDEMA; MENINGIOMA; NEUROPILIN-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR-2;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN EDEMA; CHILD; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEUROPILIN-1; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84886278946     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12052     Document Type: Article

References (32)

1. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009;9:231-40.
2. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E. Meningioma. Crit Rev Oncol Hematol 2008;67:153-71.
3. Tamiya T, Ono Y, Matsumoto K, Ohmoto T. Peritumoral brain edema in intracranial meningiomas: effects of radiological and histological factors. Neurosurgery 2001;49:1046-51, discussion 51-2.
4. Ding YS, Wang HD, Tang K, Hu ZG, Jin W, Yan W. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci 2008;38:344-51.
5. Goldman CK, Bharara S, Palmer CA, Vitek J, Tsai JC, Weiss HL, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 1997;40:1269-77.
6. Nassehi D, Dyrbye H, Andresen M, Thomsen C, Juhler M, Laursen H, et al. Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS 2011;119:831-43.
7. Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol 2004;70:349-57.
8. Sakuma T, Nakagawa T, Ido K, Takeuchi H, Sato K, Kubota T. Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas. J Neurooncol 2008;88:143-55.
9. Fons P, Herault JP, Delesque N, Tuyaret J, Bono F, Herbert JM. VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 2004;200:351-9.
10. Hess AP, Schanz A, Baston-Buest DM, Hirchenhain J, Stoff-Khalili MA, Bielfeld P, et al. Expression of the vascular endothelial growth factor receptor neuropilin-1 in the human endometrium. J Reprod Immunol 2009;79:129-36.
11. Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins: structure, function and role in disease. Biochem J 2008;411:211-26.
12. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
13. Staton CA, Kumar I, Reed MW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J Pathol 2007;212:237-48.
14. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007;11:53-67.
15. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008;88:339-47.
16. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
17. Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, Clarke D, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 2012;34:221-37.
18. Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009;94:63-8.
19. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A. Meningiomas. In: WHO Classification of Tumours of the Central Nervous System, Louis DN, H Ohgaki, OD Wiestler, WK Cavenee, editors. Lyon: IARC, 2007: 164-72.
20. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988;96:857-81.
21. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005;21:389-95.
22. Hasselblatt M, Nolte KW, Paulus W. Angiomatous meningioma: a clinicopathologic study of 38 cases. Am J Surg Pathol 2004;28:390-3.
23. Probst-Cousin S, Villagran-Lillo R, Lahl R, Bergmann M, Schmid KW, Gullotta F. Secretory meningioma: clinical, histologic, and immunohistochemical findings in 31 cases. Cancer 1997;79:2003-15.
24. Regelsberger J, Hagel C, Emami P, Ries T, Heese O, Westphal M. Secretory meningiomas: a benign subgroup causing life-threatening complications. Neuro Oncol 2009;11:819-24.
25. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol 2000;50:109-20.
26. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007;282:26294-305.
27. Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathol 2011;28:99-106.
28. Barresi V, Tuccari G. Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology 2010;30:537-46.
29. Barresi V, Vitarelli E, Cerasoli S. Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density. Virchows Arch 2009;454:563-71.
30. Preusser M, Hassler M, Birner P, Rudas M, Acker T, Plate KH, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol 2012;31:352-60.
31. Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 2006;6:152.
32. Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 1993;33:212-7, discussion 17-8.